3SOF

Hevy volume .... 13 Mil  above average volume Rock on!!!

Terlisa, thanks for the charts. Keep up the good work Applaud

Generex Biotechnology Subsidiary Receives Patent From European Patent Office
Monday May 1, 7:30 am ET


Award in Ii-Key Hybrids Technology to Regulate Antigen Presentation by Immunoregulatory Cells


TORONTO--(MARKET WIRE)--May 1, 2006 -- Generex Biotechnology Corporation (NasdaqSC:GNBT - News) announced today that its wholly owned subsidiary, Antigen Express, Inc., has been granted a European patent titled "Regulation of Antigen Presentation." The patent issued on December 21, 2005 relates to the use of Ii-Key peptides in regulating antigen presentation. It broadly covers the use of Ii-Key in potential immunotherapy treatments of cancer and infectious diseases.
ADVERTISEMENT


Antigen Express is pursuing novel immunotherapeutics based on the antigen-specific stimulation of T helper cells. The use of Ii-Key to augment the potency of antigenic peptides constitutes one of two platform technologies being developed at the Company. The most advanced of these projects employs an Ii-Key modified peptide from the tumor-associated HER-2/neu protein. That compound has been in the clinic for a year in patients with breast cancer and has shown good activity in stimulating T helper cells to specifically recognize HER-2/neu. A similar vaccine employing Ii-Key and a fragment of the H5 protein from the H5N1 virus is being developed as a prophylactic vaccine for the potentially pandemic H5N1 avian influenza virus.

About Generex

Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Oral-lyn(TM)), which has been approved for commercial sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. Antigen Express is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases.

For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

Strong close on GNBT @ 3.10
Volume 17,429,533 Million  ...yahoooo.............

Quote from: Terlisa on May 01, 2006, 04:02:16 PM
Strong close on GNBT @ 3.10
Volume 17,429,533 Million  ...yahoooo.............

Had to love the strong close you buy in this today Terlisa? I got in at 2.90.

The chart is looking ready for another bull run  breaking out of this consolidation pattern on heavy volume and a strong candle.

-fous

Quote from: fous on May 01, 2006, 05:22:41 PM

Had to love the strong close you buy in this today Terlisa? I got in at 2.90.

The chart is looking ready for another bull run  breaking out of this consolidation pattern on heavy volume and a strong candle.

-fous

Yap...I did, a little earlier than you @ 2.83

Hi everybody!!  Someone can tell me which could be a good target price for GNBT???

Thanks!!!

I noticed that as soon as that story about bird flu in New Jersey hit, the whole bird flu group moved up, but only NVAX and GNBT looked convincing.

QuoteMild Form Of Bird Flu Found In New Jersey

May 1, 2006


Julie Farby - All Headline News Staff Writer

New York, NY (AHN)—New Jersey's agriculture department's says authorities have discovered a mild form of avian influenza at a live bird market in the state, but it is not the deadly H5N1 strain governments around the world are trying to contain.

New Jersey's Agriculture Secretary Charles Kuperus says, "The strain was found in a live bird market in Camden County. None of the birds in the market died from this virus, which is an indicator that the virus was low pathogenic and not harmful to humans."

The H5N1 strain of avian influenza not only kills chickens quickly, but can now infect people, and governments around the world are scrambling to contain its spread. The H5N1 avian flu strain has already infected 205 people and killed 113 since 2003.

According to the report, Kuperus says preliminary tests from the National Veterinary Services laboratory were negative for type N1 of the virus, adding that more tests are pending at laboratories of the U.S. Agriculture Department in Ames, Iowa, to confirm the strain of the virus.

Chart looks pretty decent, I think I like GNBT over NVAX (from a TA perspective).

GNBT:

Clinician Presents Generex Oral-lyn(TM) Clinical Data at the Pediatric Academic Societies' 2006 Annual Meeting

TORONTO, May 02, 2006 (MARKET WIRE via COMTEX) -- Generex Biotechnology Corporation (GNBT : generex biotechnology cp del com
News , chart, profile, more
Last: 3.10+0.44+16.54%

8:03am 05/02/2006

GNBT3.10, +0.44, +16.5%) , a leader in the area of buccal drug delivery, announced today that Dr. Jaime Guevara-Aguirre, M.D., of the Institute of Endocrinology IEMYR in Quito, Ecuador, was invited to make a late-breaker platform presentation of Generex Oral-lyn(TM) clinical data on May 1, 2006 at the Pediatric Academic Societies' 2006 Annual Meeting in San Francisco.
Dr. Guevara's presentation was entitled "Preliminary Results from a 6-Month Study on the Safety and Efficacy of an Oral Insulin (Generex Oral-lyn(TM)) Administered at Lunch Time in Adolescent and Young Adult Type-1 Diabetes Mellitus Subjects Maintained on Basal Subcutaneous Glargine Insulin and Pre-Breakfast and Pre-Dinner Subcutaneous Regular Insulin."
"We are most gratified that the scientific community has recognized the importance of this study and the significance of these preliminary results and invited the principal investigator to make a podium presentation of the clinical data at this important scientific symposium," said Anna Gluskin, President & Chief Executive Officer of Generex.
Participating subjects in this 6-month study are 24 adolescents (12M; 12F) and five young adults (2M; 3F) referred to the Institute of Endocrinology IEMYR in various degrees of metabolic control as reflected by altered baseline measurements of glucose 236.6 (116.6) mg/dL; fructosamine 472.6 (126.6) umol/L; and glycosylated hemoglobin (HbA1c) 9.8 (2.3) g/dL. Baseline demographics of the 24 adolescents are: Age 14.7y (2.1); Bone age 14.1 (2.2); CA/BA 1.0 (0.1); Height 153.8cm (9.4); Weight 51.0kg (10.2); BMI 21.7 (3.2); Duration of DM 6.7 (2.. Baseline demographics of the 5 young adults are: Age 20.6y (2.2); Bone age (BA) 18.8 (0.4); CA/BA 1.1 (0.1); Height 161.1cm (12.; Weight 62.5kg (9.3); BMI 23.0 (1.; Duration of DM 7.0 (1.7). Mean age for the entire group is 15.7y (3.0); BA 14.9 (2.7); CA/BA 1.1 (0.1); Duration of the DM is 6.8 (2.6).
After stabilization with basal subcutaneous glargine insulin and three pre-prandial subcutaneous regular insulin injections, standard therapy continued for four weeks for comparison. Immediately thereafter, split doses of Generex Oral-lyn immediately before and after lunch replaced lunch time injections of regular insulin. Patient-collected glucose values, fructosamine, and HbA1c were compared weekly (3-4 weeks per each treatment). Values are reported at the end of each phase.
FRUCTOSAMINE     HbA1C      GLUCOSE (BASAL)
PHASE            MEAN      SD  MEAN    SD      MEAN     SD
BASELINE       476.89  130.22   9.9  2.38     236.6* 116.5
REGULAR
INSULIN        368.2      91   8.4   1.6     140.4   35.5
ORAL-LYN        379.1     133   8.5   2.1     143.3   39.9
COMPARED
TO BASELINE          < .0001     < .0001          < .0005
10-WEEK DATA    377.9      98   7.9   1.6


(*Glucose values at baseline were determined by laboratory; other glucose values were determined by glucometer)
After comparison, a 6-month study of Generex Oral-lyn treatment at lunchtime was initiated. Fructosamine and HbA1c results between the 8th and 10th week of treatment demonstrated that fructosamine and HbA1c levels maintain the trend towards normalization.
In summary, successful replacement of regular subcutaneous insulin with Generex Oral-lyn during the initial 10 weeks of this 6-month trial was achieved as demonstrated by patient-collected glucose levels, fructosamine, and HbA1c measurements.
In addition to the podium presentation, Dr. Guevara made a poster presentation at the symposium of a study entitled "A 12-Day Comparison of Preprandial Humulin-R(R) vs. Generex Oral-lyn(TM) in 10 Type-1 Diabetic Subjects Receiving Baseline Glargine Insulin Therapy."
The aim of this pilot study was to determine the suitability of dose and formulation of Generex Oral-lyn for its use in a larger multi-center trial. The study also compared the glucodynamics of both rapid insulins (Generex Oral-lyn and Humulin-R(R)) in 10 Type-1 diabetic subjects receiving glargine insulin as their baseline therapy. Fructosamine, a parameter of protein glycation, was determined as part of a panel of safety monitoring.
10 Type-1 Diabetes Mellitus (DM) research subjects received their usual baseline glargine insulin (Lantus(R)) therapy twice daily (BID: 2/3rd in the morning and 1/3rd in the evening). Depending on present glycemia, Humulin-R was dosed as a pre-meal subcutaneous injection during days -3, -2 and -1. Five to eight puffs of Generex Oral-lyn were given pre- and post-prandially on days +1 through +9. Adjustments of glycemia were done using standard snacks, additional subcutaneous Humulin-R or Generex Oral-lyn puffs.
Peripheral glucose measurements were self-monitored by the 10 DM Type-1 research subjects in duplicate at each time-point by using a common standard method (Accu-Chek(R)). The peripheral glucose concentration average of the 2-value performed at each time-point for the 9-day Generex Oral-Lyn (O), and 3-day Humulin-R (H) are hereby provided: Pre-Breakfast (B): 70.26 (O) vs. 91.08 (H); 1-hour (h) post-B: 138.50 (O) vs. 151.45 (H) ; 2-h post-B: 113.92 (O) vs. 108.18 (H); Pre-Lunch (L): 84.82 (O) vs. 98.55 (H); 1-post-L: 142.00 (O) vs. 140.77 (H); 2-h post-L: 113.55 (O) vs. 106.28 (H); Pre-Dinner (D): 92.84 (O) vs. 100.78 (H); 1-post-D: 141.31 (O) vs. 139.43 (H); 2-h post-D: 119.62 (O) vs. 109.94 (H). The corresponding Area Under the Curve for both treatments were compared and no statistical significance was found (p = 0.6875).
Using BID glargine insulin (Lantus) as baseline therapy, Humulin-R and Generex Oral-lyn induced similar glucodynamic responses during the 12-day observation period. Intensive monitoring and timely corrections with additional snacks, Humulin-R or Generex Oral-lyn resulted in an appropriate glycemic control as assessed by individual daily-glycemic curves and, especially, normal preprandial glycemia. Measurements of protein glycosylation displayed a tendency to lower values after the 12-day study period.

Any thoughts on the late afternoon sell-off? 

I am watching for a new entry point, any suggestions?  looks good where it closed today, but I am not sure why the sudden drop, 

I couldn´t find the reason for the drop but I was stopped out yesterday...


GNBT: Volume Spike; 14% > 20-adsv, Stock -17.69%
Thursday , May 11, 2006 11:05 ET

This is the 3rd VOLUME alert for GNBT in the past 7 calendar days.

Trading for Generex Biotechnology Corporation (NASDAQ SC: GNBT) has been heavier than usual in today's session. By 11:05 ET, the stock had already traded 6,307,000 shares via 3,374 trades. The cumulative volume is 13.80% above its 20-day average of 5,542,310. Normally the stock experiences around 2,796 individual trades per session.

So far, today's volume surge has caused a net decline in GNBT's stock price. At the time of this alert, the stock was trading at $2.140, down $-0.460 (-17.69%).

One year ago, the Company's shares closed at $0.819. The price has gained more than 161 percent since then.

Over the last 10 trading session GNBT has traded in a range between $2.530 and $3.250 and is currently trading 57.37% below its 52-week high of $5.020 set on March 22,2006 and 303.77% above its 52-week low of $0.530 from August 19,2005.

In the previous 3 sessions, GNBT trading has displayed a mixed trend. Closing results have been as follows:

May 10, 2006 --- closed at $2.600 down $0.130 (-4.76%) on 6,172,400 shares
May 09, 2006 --- closed at $2.730 up $0.060 (+2.25%) on 3,987,900 shares
May 08, 2006 --- closed at $2.670 down $0.280 (-9.49%) on 6,942,100 shares

7:33AM Generex Biotech announces its subsidiary presents avian influenza vaccine program at Embassy Briefing (GNBT) 2.27 : Co announced today that Dr. Eric von Hofe, the President of Antigen Express, its wholly owned immunotherapeutics subsidiary, made an invited presentation this week of the co's synthetic avian influenza program at an embassy briefing hosted by Sandler, Travis & Rosenberg, P.A. in Washington, D.C. The co is currently conducting late-stage pre-clinical studies on the vaccine and has been in discussions with the FDA in respect of preparations for the filing of an Investigation New Drug Application for the vaccine.

Move today may be due to speculation of Human to Human bird flu cases in Indonesia.

http://www.bloomberg.com/apps/news?pid=10000080&sid=aWESsJvt6CFE&refer=asia